Help Us Make Change in Myeloma Research Today on #GivingTuesday

LIFE WITH MYELOMA - November 30, 2021

Help us make Change in Multiple Myeloma Research Today on #GivingTuesday Please help us reach our matching grant of $200,000 for a total fundraise of $400,00... Read More

One Patient’s Motivation: BBC Profiles Jenny Ahlstrom

“It took me eight years to get up to speed on myeloma, and that’s not fair for other patients.”            ... Read More

Join Us Live or Online for the Miami MCRT on January 22

Get away from the winter doldrums in sunny Florida for the first-ever Myeloma Crowd Round Table in Miami, Florida on Saturday, January 22, 2022 at the Hilton Av... Read More

Tips and Tools to Manage Loneliness During the Holidays

MYELOMA COACH - November 27, 2021

This time of year brings hustle, bustle, food, and family gatherings. For some, it is a joyful, full time and for others a time of loneliness. Whether... Read More

HealthTree University: Specific Myeloma Genetics Mutations and Risk (3/3)

HEALTHTREE - November 27, 2021

Did you know that the genetics of your myeloma affect how high-risk or low-risk your disease is? Some of the top myeloma doctors in the world answered our quest... Read More

Giving Tuesday - The History

MCRI - November 26, 2021

This November 30th, we will be celebrating Giving Tuesday. On this global day of giving, the Myeloma Crowd by HealthTree is working to raise $400,000 to make re... Read More

A Potential Warning Sign for Allo CAR T in Multiple Myeloma

MYELOMA NEWS - November 24, 2021

Myeloma Crowd by HealthTree has posted several articles recently here and here about the potential of donor CAR-T cell therapy. These CAR-T cells have the ... Read More

One Week From #GivingTuesday - The Largest Donation Day of the Year!

LIFE WITH MYELOMA - November 23, 2021

  Donate to Myeloma Research on #GivingTuesday   The holiday season is just around the corner, and we invite you to kick it off with us one w... Read More

Dual Myeloma CAR T Targeting BCMA and CD19 Gets FDA Orphan Drug Designation

MYELOMA NEWS - November 23, 2021

  China-based Gracell Biotechnologies was recently given FDA Orphan Drug designation for a dual CAR T targeting BCMA and CD19 in multiple myelom... Read More

Full Show: A Smoldering Myeloma Update with Elisabet Manasanch, MD, MD Anderson Cancer Center

MC RADIO - November 21, 2021

Elisabet Manasanch, MD,  MD Anderson Cancer Center Interview Date: October 27, 2021 Thanks to our episode sponsor Summary Smoldering myeloma... Read More

ASH 2021: Myeloma Antibody Symposium Kicks Off ASH for HealthTree Foundation

MC EVENTS - November 19, 2021

Antibody-based cancer treatment updates will be among the stars of the show for myeloma physicians and researchers attending the American Society of Hematology ... Read More

New Genetic Subdivisions Help Separate Myeloma Risk and Potentially Personalize Treatments

MYELOMA NEWS - November 19, 2021

Mount Sinai researchers have identified new ways of classifying myeloma sub-types to define risk in a paper published in Science Advances.  The new tool, c... Read More

Clinical Trial: A New Myeloma Therapy Tasquinimod Targeting MDSCs


A new oral treatment that targets the tumor microenvironment and changes the immune system called tasquinimod is now in early multiple myeloma clinica... Read More

Find Myeloma Help

Myeloma Financial Resource


Find financial resources like housing, prescription and patient assistance programs and other helpful links that will guide you through your myeloma care.

Myeloma Specialist


Patients who are seen by myeloma specialists live longer. Find a myeloma specialists closest to you and add them to your care team for your best outcomes.

Myeloma Clinical Trials


Find personally relevant treatment options and clinical trials at every stage of your myeloma with HealthTree and SparkCures.

Myeloma Coach


We're a team of myeloma patient and caregiver volunteers who can help you find and use the best myeloma resources so you can better navigate your myeloma care.

Thanks to our Myeloma Crowd Community sponsors:

.                         .       .